Business Wire

CGTN

Share
CGTN: 'Reform and Opening-Up' Remains Theme of Xi Jinping's Visit to China's Guangdong Province

Chinese President Xi Jinping on Monday arrived in south China's Guangdong Province to begin his inspection tour, his 12th domestic visit this year and his third to Guangdong since the 18th National Congress of the Communist Party of China (CPC).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201012005890/en/

"Reform and opening-up" remained the keywords during his three visits to Guangdong in 2012, 2018, 2020, respectively.

Read the original article here .

Protecting cultural legacy

During this visit, President Xi visited cultural and historical landmarks in the city of Chaozhou, including an ancient bridge, an ancient gate tower and a street lined with ancient archways, to check on the restoration and protection of cultural relics, the inheritance of intangible cultural heritage and the development of cultural and tourism resources.

The president has always insisted that the protection and exploration of cultural heritage assets must serve a country's development.

In October 2018, Xi stressed that more importance should be attached to preserving history and culture during urban planning and construction during his visit to Xiguan historical and cultural community in the Liwan District of Guangzhou City, Guangdong Province.

During this National Day and Mid-Autumn Festival holiday, the ancient township of Chaozhou received nearly 2 million tourists with a total revenue of some 890 million yuan, with its cultural charm.

The president underscored that the development of tourism should be based on protection and should not be over-commercialized when he visited the Yungang Grottoes, where he learned about historical and cultural heritage protection efforts in north China's Shanxi Province in May this year.

China's reform and opening-up paragon

President Xi also visited Chaozhou Three-Circle (Group) Co., Ltd., an electronic components and communication device manufacturer, checking out the company's indigenous innovation, production and operation.

In 2019, Guangdong's provincial GDP exceeded 10 trillion yuan (about $1.48 trillion). Under the current poverty threshold, over 1.6 million relatively poor people have reached the alleviation standard, a decisive victory in the battle against poverty.

In December 2012, President Xi visited Guangdong's Shenzhen during his first around-the-country tour after he was elected the CPC leader.

Two years ago, when China marked the 40th anniversary of reform and opening-up, he revisited the city and emphasized the need to keep promoting the process of reform and opening-up.

"I come to visit Shenzhen as it marks the 40th anniversary of reform and opening-up to tell the world that China will not stop its reform and opening-up. China will certainly deliver a bigger miracle that draws worldwide attention," he said.

Shenzhen is an important stop during his latest inspection tour to Guangdong Province.

On Wednesday morning, the president will attend a grand gathering celebrating the 40th anniversary of the establishment of the Shenzhen Special Economic Zone.

On August 26, 1980, the 15th meeting of the Standing Committee of the fifth National People's Congress, the national legislature, approved the establishment of special economic zones in Shenzhen, Zhuhai and Shantou in Guangdong Province and Xiamen in Fujian Province.

Over the past four decades, Shenzhen has been transformed from a small fishing village to a modern metropolis with a population of over 13 million.

Social Media:

https://www.facebook.com/ChinaGlobalTVNetwork/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye